Neurogene NGNE
NASDAQ NGNE
$38.60 +0.99 (+2.63%)
At close: Sep 4, 2026 · 4:00 PM EDT

Neurogene (NGNE) Debt Ratio (2013)

Neurogene's (NGNE) quarterly Debt Ratio came in at 0.15 in Q4 2013.

Analysis

Neurogene (NGNE) Debt Ratio (2013) Analysis & Trends

Neurogene (NGNE) has 1 years of Debt Ratio data on file, last reported at 0.15 in Q4 2013.

  • Quarterly Debt Ratio changed N/A year-over-year to 0.15 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was 0.15 (changed N/A YoY) and the FY2013 annual result came in at 0.15, changed N/A from the prior year.
  • Debt Ratio steadied at 0.15 in Q4 2013.
  • In the past five years, Debt Ratio ranged from a high of 0.15 in Q4 2013 to a low of 0.15 in Q4 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 0.05
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 0.05
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 0.12
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 0.47
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 0.26
10 Neurogene 864.53 Mn 864.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 0.15